Arylsulfatase B controlled release - Hanmi Pharmaceutical

Drug Profile

Arylsulfatase B controlled release - Hanmi Pharmaceutical

Alternative Names: HM15450

Latest Information Update: 05 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Arylsulfatases; Enzymes
  • Mechanism of Action Arylsulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mucopolysaccharidosis VI

Most Recent Events

  • 05 Jun 2017 Preclinical trials in Mucopolysaccharidosis VI in South Korea before June 2017 (Hanmi Pharmaceutical pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top